OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors
Blessie Elizabeth Nelson, Funda Meric‐Bernstam
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 31-48
Closed Access | Times Cited: 10

Showing 10 citing articles:

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2860-2872
Open Access | Times Cited: 29

Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3

Antibody-drug conjugates in breast cancer: current evidence and future directions
Ning Li, Lu Yang, Zixuan Zhao, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1

Contemporary management of advanced gastric and gastroesophageal adenocarcinomas
Jane E. Rogers, Jaffer A. Ajani
Expert Review of Anticancer Therapy (2025), pp. 1-7
Closed Access

Modular assembly and evaluation of a TROP2-targeting immunotoxin for cancer therapy
Yajie Deng, Zi Hui, Lu Liu, et al.
International Journal of Biological Macromolecules (2025), pp. 143311-143311
Closed Access

Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook
Yongshun Liu, Wenpeng Huang, Rachel J. Saladin, et al.
Molecular Pharmaceutics (2024) Vol. 21, Iss. 12, pp. 5909-5928
Closed Access | Times Cited: 1

Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation
Wei Huang, Min Cao, Yanfei Wu, et al.
Journal of Nuclear Medicine (2024), pp. jnumed.124.268751-jnumed.124.268751
Closed Access | Times Cited: 1

Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models
Funda Meric‐Bernstam, Erkan Yuca, Kurt W. Evans, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 3, pp. 573-587
Open Access | Times Cited: 1

Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy
Yehao Yang, Ying Yu, Yun Fan, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189145-189145
Open Access

Page 1

Scroll to top